Cen­tu­ry Ther­a­peu­tics nabs Bris­tol My­ers alum as CEO; En­her­tu star Dai­ichi Sankyo makes changes in Eu­rope

→ Cen­tu­ry Ther­a­peu­tics an­nounced the de­par­ture of CEO La­lo Flo­res in April, and the Philadel­phia cell ther­a­py biotech has found his suc­ces­sor. Brent Pfeif­f­en­berg­er just spent the last two years as COO of Neo­gene Ther­a­peu­tics, the US/Dutch TCR spe­cial­ist that’s now a sub­sidiary of As­traZeneca, and he led the US on­col­o­gy busi­ness at the tail end of an 18-year ca­reer with Bris­tol My­ers Squibb. Chaired by ex-No­var­tis chief Joe Jimenez, Cen­tu­ry elim­i­nat­ed 25% of its staff in Jan­u­ary and brought back Hy Lev­it­sky as pres­i­dent of R&D in ad­di­tion to the CEO change. In­ter­im chief ex­ec­u­tive Greg Rus­sot­ti will now be chief tech­nol­o­gy and man­u­fac­tur­ing of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER